- Home
- MIRA vs OCEA Comparison
MIRA vs OCEA Comparison
Compare MIRA & OCEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- OCEA
- Stock Information
- Founded
- MIRA 2020
- OCEA 2019
- Country
- MIRA United States
- OCEA United States
- Employees
- MIRA N/A
- OCEA N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- OCEA Biotechnology: Pharmaceutical Preparations
- Sector
- MIRA Health Care
- OCEA Health Care
- Exchange
- MIRA Nasdaq
- OCEA Nasdaq
- Market Cap
- MIRA 18.4M
- OCEA 20.5M
- IPO Year
- MIRA 2023
- OCEA N/A
- Fundamental
- Price
- MIRA $1.10
- OCEA $0.13
- Analyst Decision
- MIRA Strong Buy
- OCEA
- Analyst Count
- MIRA 2
- OCEA 0
- Target Price
- MIRA $14.00
- OCEA N/A
- AVG Volume (30 Days)
- MIRA 226.5K
- OCEA 88.9M
- Earning Date
- MIRA 03-31-2025
- OCEA 01-13-2025
- Dividend Yield
- MIRA N/A
- OCEA N/A
- EPS Growth
- MIRA N/A
- OCEA N/A
- EPS
- MIRA N/A
- OCEA N/A
- Revenue
- MIRA N/A
- OCEA N/A
- Revenue This Year
- MIRA N/A
- OCEA N/A
- Revenue Next Year
- MIRA N/A
- OCEA N/A
- P/E Ratio
- MIRA N/A
- OCEA N/A
- Revenue Growth
- MIRA N/A
- OCEA N/A
- 52 Week Low
- MIRA $0.51
- OCEA $0.11
- 52 Week High
- MIRA $5.01
- OCEA $7.79
- Technical
- Relative Strength Index (RSI)
- MIRA 43.36
- OCEA 28.02
- Support Level
- MIRA $1.09
- OCEA $0.12
- Resistance Level
- MIRA $1.18
- OCEA $0.16
- Average True Range (ATR)
- MIRA 0.06
- OCEA 0.04
- MACD
- MIRA -0.00
- OCEA 0.01
- Stochastic Oscillator
- MIRA 7.69
- OCEA 8.66
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About OCEA Ocean Biomedical Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.